RxDoctor Payments Data

Gregory Lauwers, MD

Anatomic Pathology · Boston, MANPI 1841280674

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,800 of the $26,700 with a category attached, or 96.6%. Pfizer accounts for 95.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $21,700 and has fallen 90.8% since, to $2,000 in 2023. Among anatomic pathology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,700in general payments, 2019–2025

Across 11 payments — averaging $2427.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$25K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$1K
$589,500in research payments, 2019–2025

Across 43 payments — averaging $13,709 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$300K
  • Eli Lilly$250K
  • Celltrion, Inc.$40K

What the payments were for

  • Consulting fees$25,80097%
  • Speaking & faculty fees$9003%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer9$25,400
Boehringer Ingelheim Pharma GmbH & Co.kg2$1,300

How this compares

$26,700 in reported general payments places this provider in the 90th percentile of 119 anatomic pathology providers in Massachusetts.

See all anatomic pathology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$152,695
Medicare patients
957
Services billed
3,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →